Pennell C A, Scott D W
Eur J Immunol. 1986 Dec;16(12):1577-81. doi: 10.1002/eji.1830161217.
CH31 and CH33 are B cell lymphomas whose growth in vitro is inhibited by anti-Ig reagents, including both polyclonal and monoclonal anti-mu antibodies, and an anti-idiotype antiserum. Antibodies against class I or class II major histocompatibility complex antigens do not affect the growth of these cells. Inhibition is dependent on surface Ig cross-linking and does not require ligand binding to Fc receptors. Interestingly, the inhibition of growth by anti-mu is reversed in CH31 (but not CH33) by E. coli lipopolysaccharide. These lymphomas should provide excellent models to study the mechanisms of growth inhibition mediated by surface Ig cross-linking and the pathways of its reversal.
CH31和CH33是B细胞淋巴瘤,其体外生长受到抗Ig试剂的抑制,这些试剂包括多克隆和单克隆抗μ抗体以及一种抗独特型抗血清。针对I类或II类主要组织相容性复合体抗原的抗体不影响这些细胞的生长。抑制作用依赖于表面Ig交联,且不需要配体与Fc受体结合。有趣的是,在CH31(而非CH33)中,大肠杆菌脂多糖可逆转抗μ对生长的抑制作用。这些淋巴瘤应为研究表面Ig交联介导的生长抑制机制及其逆转途径提供极佳的模型。